Geopolitics Alpha

What Oncocyte (IMDX) Said on Its Q3 Earnings Call

Published . Updated .

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.

What Oncocyte (IMDX) Said on Its Q3 Earnings Call

Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration’s request for more information about its GraftAssureDx kidney transplant test, executives said on the company’s third-quarter earnings call. President

Directly affected

  • IMDX Insight Molecular Diagnostics

    Named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR holds the health sector that Insight Molecular Diagnostics belongs to, so it often moves with news about it.

  • IDXX IDEXX Laboratories+30.8% 14d

    IDEXX Laboratories is a peer of Insight Molecular Diagnostics in in vitro and in vivo diagnostic substances; rivals often move on the same news.

  • LNTH Lantheus Holdings+1.3% 30d

    Lantheus Holdings is a peer of Insight Molecular Diagnostics in in vitro and in vivo diagnostic substances; rivals often move on the same news.

  • NEOG Neogen-6.5% 30d

    Neogen is a peer of Insight Molecular Diagnostics in in vitro and in vivo diagnostic substances; rivals often move on the same news.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
IMDX+34.05%+24.32%baseafter closeafter closeafter closeafter close
XLV+0.52%-0.04%baseafter closeafter closeafter closeafter close
IDXX-0.56%-0.37%baseafter closeafter closeafter closeafter close
LNTH-0.12%-0.49%baseafter closeafter closeafter closeafter close
NEOG+7.26%+2.94%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

What Oncocyte (IMDX) Said on Its Q3 Earnings Call Yahoo Finance

Source: Yahoo Finance

This story

CompanyWhenMoveStatus
IDXXthree days earlier-0.37%final price
IDXXfive days earlier-0.56%final price
IMDXthree days earlier+24.32%final price
IMDXfive days earlier+34.05%final price
LNTHthree days earlier-0.49%final price
LNTHfive days earlier-0.12%final price
NEOGthree days earlier+2.94%final price
NEOGfive days earlier+7.26%final price
XLVthree days earlier-0.04%final price
XLVfive days earlier+0.52%final price

Congressional trades in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

How solid “What Oncocyte (IMDX) Said on Its Q3 Earnings Call” looks

12 out of 100

“What Oncocyte (IMDX) Said on Its Q3 Earnings Call” scores 12 out of 100. The score uses 1 sources.